Home > Insider Trading > Filing (0001415889-24-028844)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1730430	Kiniksa Pharmaceuticals International Plc	KNSA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1835458	Mark Ragosa	23 Old Bond Street, Third Floor London X0 W1S 4PZ	Chief Financial Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Ordinary Share	Acquisiton	2024-12-06	2,406	$10.76	25,364	No	4	M	Direct
Class A Ordinary Share	Disposition	2024-12-06	8,969	$21.27	22,958	No	4	S	Direct
Class A Ordinary Share	Acquisiton	2024-12-09	18,860	$11.10	41,818	No	4	M	Direct
Class A Ordinary Share	Disposition	2024-12-09	18,860	$21.38	22,958	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Ordinary Share	Share Option	Disposition	2024-12-06	2,406	$0.00	2,406	$10.76
Class A Ordinary Share	Share Option	Disposition	2024-12-09	18,860	$0.00	18,860	$11.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
24,528		2033-03-31	No	4	M	Direct
21,552		2032-04-06	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.31. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.755. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023.
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 8, 2022.